NCT01525589 - A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

June 13, 2012

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions

Breast Cancer

Interventions

DRUG

PM01183

PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial

Trial Locations (9)

Weill Cornell Medical College - New York Presbyterian Hospital, New York

Complexo Hospitalario Universitario A Coruña, A Coruña

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

Abramson Cancer Center - Hospital of the University of Pennsylvania at Perelman Center for Advanced Medicine, Philadelphia

Hospital Clínico Universitario de Valencia, Valencia

The University of Texas MD Anderson Cancer Center, Houston

Stanford Women's Cancer Center, Stanford

Massachusetts General Hospital, Boston

Hospital Universitari Vall d'Hebron, Barcelona